Subscribe to RSS
DOI: 10.1055/s-2004-832304
© Georg Thieme Verlag Stuttgart · New York
The Role of L1 in the Progression of Ovarian Carcinomas
Die Funktion von L1 bei der Progression des OvarialkarzinomsPublication History
Publication Date:
12 October 2004 (online)
Abstract
The L1 molecule has recently emerged as a promising new biomarker for the prognosis of human ovarian and endometrial tumors. It was initially described as an adhesion molecule for the development of the nervous system but its function in tumor cells is not well known. In this article we summerize recent data on the role of L1 in promoting tumor cell adhesion and migration and in gene regulation. We address the question how L1 determination in tumor tissue samples and in serum and ascites could potentially improve the disease management.
Zusammenfassung
L1 ist ein neuer Biomarker für die Prognose bei Patienten mit Ovarial- und Endometriumskarzinom. Ursprünglich wurde L1 als neuronales Adhäsionsmolekül mit großer Bedeutung für die Entwicklung des Nervensystems beschrieben. Die Funktion auf Karzinome ist bisher unbekannt. In diesem Artikel fassen wir die aktuellen Daten zur Funktion von L1 bei der Zellmigration und der Genregulation zusammen. Wir diskutieren auch die Möglichkeit von verbesserter Diagnose und Therapie von Ovarialkarzinomen basierend auf L1.
Key words
L1 - ADAM10 - shedding - cell migration - ovarian and endometrial carcinoma
Schlüsselwörter
L1 (CD171) - ADAM10 - Zellmigration - Ovarial- und Endometriumskarzinom
References
- 1 Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, BenArie A, Huszar M, Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003; 362 869-875
- 2 Beer S, Oleszewski M, Gutwein P, Geiger C, Altevogt P. Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. J Cell Sci. 1999; 112 2667-2675
- 3 Schlöndorff J, Blobel C P. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci. 1999; 112 3603-3617
- 4 Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V, Altevogt P. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol. 2001; 155 661-674
- 5 Debiec H, Christensen E I, Ronco P M. The cell adhesion molecule L1 is developmentally regulated in the renal epithelium and is involved in kidney branching morphogenesis. J Cell Biol. 1998; 143 2067-2079
- 6 DiSciullo G, Donahue T, Schachner M, Bogen S A. L1 antibodies block lymph node fibroblastic reticular matrix remodeling in vivo. J Exp Med. 1998; 187 1953-1963
- 7 Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S, Zentgraf H, Fogel M, Altevogt P. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. Faseb J. 2003; 17 292-294
-
8 Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery A M. ERK-regulated gene expression contributes to L1-CAM dependent motility and invasion. J Biol Chem 2004; 28880-28888
- 9 Primiano T, Baig M, Maliyekkel A, Chang B D, Fellars S, Sadhu J, Axenovich S A, Holzmayer T A, Roninson I B. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell. 2003; 4 41-53
Peter AltevogtPhD
Tumor Immunology Programme · D010 · German Cancer Research Center
Im Neuenheimer Feld 280
D-69120 Heidelberg
Germany
Phone: 0 62 21-42 37 14
Fax: 0 62 21-42 37 02
Email: p.altevogt@dkfz.de